
	CRITERES DE SELECTION ETUDE STEREO-OS	Identité patient (coller étiquette patient)
Version 1.0 du 02/12/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Philippe BATAILLARD Poste : 8137


« STEREO-OS »
Extracranial Stereotactic Body Radiation Therapy (SBRT) added to standard treatment versus standard treatment alone in solid tumors patients with ≤ 3 bone-only metastasis



VALIDATION DES CRITERES DE SELECTION

Critères d'inclusion :


1. Male or female patients	<input type="checkbox"/> oui <input type="checkbox"/> non
2. Age over 18 years and below 75-year old	<input type="checkbox"/> oui <input type="checkbox"/> non
3. Good general condition: WHO performance status ≤ 1	<input type="checkbox"/> oui <input type="checkbox"/> non
4. Patients with solid tumour (histological proof of breast, non-small cell lung, prostate cancer)	<input type="checkbox"/> oui <input type="checkbox"/> non
5. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery	<input type="checkbox"/> oui <input type="checkbox"/> non

	CRITERES DE SELECTION ETUDE STEREO-OS	Identité patient (coller étiquette patient)
Version 1.0 du 02/12/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Philippe BATAILLARD Poste : 8137

6. Primary tumour accessible to curative-intent treatment (surgery, chemoradiation ...)	<input type="checkbox"/> oui <input type="checkbox"/> non
7. Patients with ≤ 3 synchronous bone metastasis (1 to 3) as defined by NaF-PET and spinal MRI (if necessary)	<input type="checkbox"/> oui <input type="checkbox"/> non
8. Patients with ≤ 3 metachronous bone metastasis (1 to 3) as defined by NaF-PET and spinal MRI (if necessary)	<input type="checkbox"/> oui <input type="checkbox"/> non
9. Age over 18 years	<input type="checkbox"/> oui <input type="checkbox"/> non
10. No visceral metastasis as defined by FDG-PET (or F-Choline-PET for prostate cancer) and cerebral CT or MRI performed less than one month before SBRT	<input type="checkbox"/> oui <input type="checkbox"/> non
11. No previous systemic therapy for metastasis (neo- and adjuvant treatment allowed if metachronous metastasis). Prostate cancer patients remain eligible if hormonal treatment has already been initiated.	<input type="checkbox"/> oui <input type="checkbox"/> non

Critères de non inclusion :

1. All bone metastasis requiring surgical treatment (spinal cord compression, fracture, ...)	<input type="checkbox"/> oui <input type="checkbox"/> non
2. Symptoms requiring radiotherapy (pain...)	<input type="checkbox"/> oui <input type="checkbox"/> non
3. > 3 bone metastasis as defined by NaF-PET and spinal MRI (if spinal bone metastase on NaF-PET)	<input type="checkbox"/> oui <input type="checkbox"/> non
4. visceral metastasis on FDG-PET (F-Choline-PET for prostate cancer)	<input type="checkbox"/> oui <input type="checkbox"/> non
5. Previous cancer history within 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix)	<input type="checkbox"/> oui <input type="checkbox"/> non
6. Previous radiotherapy	<input type="checkbox"/> oui <input type="checkbox"/> non
7. Patient enrolled in another therapeutic trial	<input type="checkbox"/> oui <input type="checkbox"/> non
8. Pregnant women or women of child-bearing potential or breast feeding mothers,	<input type="checkbox"/> oui <input type="checkbox"/> non
9. Hypersensitivity to the active substance (FDG and NaF or F-Choline for prostate cancer) or to any of the excipients	<input type="checkbox"/> oui <input type="checkbox"/> non
10. Contraindication to MRI	<input type="checkbox"/> oui <input type="checkbox"/> non
11. Patient under protective custody or guardianship	<input type="checkbox"/> oui <input type="checkbox"/> non
12. Patient unable to comply with the specific obligations of the study (geographic, social or physical reasons)	<input type="checkbox"/> oui <input type="checkbox"/> non

	CRITERES DE SELECTION ETUDE STEREO-OS	Identité patient (coller étiquette patient)
Version 1.0 du 02/12/2021	Investigateur en charge du patient : PI : Dr Etienne MARTIN Mail : emartin@cgfl.fr <i>A contacter pour adresser/inclure patient externe au CGFL</i>	Arc : Philippe BATAILLARD Poste : 8137

13. Patient unable to understand the purpose of the study (language, etc.).	<input type="checkbox"/> oui <input type="checkbox"/> non
---	---

Date : _____

Signature de l'investigateur : _____